Full-Time

Associate Territory Manager

Confirmed live in the last 24 hours

Surmodics

Surmodics

201-500 employees

Provides components for diagnostics and medical devices

Compensation Overview

$99k - $149k/yr

+ Bonus Program

Junior, Mid

Houston, TX, USA

Category
Field Sales
Sales & Account Management
Required Skills
Marketing
Requirements
  • B.S. or B.A. degree, preferably in business, engineering or science-related field and/or healthcare degree or certification (i.e. nursing or technologist background)
  • 2+ years experience in medical device sales/clinical support, training, marketing or related clinical experience; cardiovascular experience preferred
  • Strong written and verbal communication, interpersonal skills
  • Computer skills appropriate for work responsibilities, including CRM software experience
  • Willingness to travel (up to 75%, dependent on territory), flexibility to accommodate a schedule that changes on short notice due to customer needs
Responsibilities
  • Assist in creating an execute effective business plans to meet and achieve sales objectives (revenue, product launches, etc.)
  • Under direction of the RD/RM or TM, Strategically and effectively launch multiple new products/product lines across geography
  • Strengthen relationship/partnership with existing accounts while building strong relationship with new customers in assigned accounts
  • Train customers and support cases to ensure appropriate use of SRDX products
  • Maintain appropriate tracking of SRDX products, to include consignment and rep stock inventory
  • Complete all required training and maintain required documentation (customer complaints, vendor credentialing, etc.)
  • Responsible for quarterly/annual forecasting of regional revenues within assigned accounts
  • Act in compliance with all laws and company rules and regulations
Desired Qualifications
  • Cardiovascular experience preferred

Surmodics specializes in providing essential components for in vitro diagnostic (IVD) products and advanced coatings for medical devices. Their IVD offerings include a variety of products such as protein stabilizers, diluents, blockers, substrates, and antibodies, which are vital for creating sensitive immunoassays that detect substances in biological samples. Surmodics also develops advanced coatings for medical devices, including lubricious and hemocompatible coatings, and is known for creating the drug delivery coating for the first drug-eluting stent. The company collaborates closely with clients to accelerate product development and commercialization, which helps them bring their products to market faster. Surmodics stands out from competitors through its strong focus on client collaboration and rapid timelines for product development, aiming to support the success of its clients in the healthcare and biotechnology sectors.

Company Size

201-500

Company Stage

IPO

Headquarters

Eden Prairie, Minnesota

Founded

1979

Simplify Jobs

Simplify's Take

What believers are saying

  • Surmodics' Pounce thrombectomy systems address rising peripheral artery disease cases.
  • The SurVeil DCB shows promising results, boosting interest in drug-coated balloons.
  • New Preside hydrophilic coatings tap into the expanding neurovascular device market.

What critics are saying

  • Increased competition in thrombectomy devices may impact Surmodics' market share.
  • GTCR acquisition could disrupt client relationships or alter company focus.
  • Rapid innovation in drug-eluting technologies may outpace Surmodics' current offerings.

What makes Surmodics unique

  • Surmodics excels in surface modification and drug-delivery coating technologies.
  • The company offers a unique combination of IVD products and advanced medical device coatings.
  • Surmodics' close client collaboration accelerates product development and commercialization.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

401(k) Company Match

401(k) Retirement Plan

Company Equity

Stock Options

Company News

Urall News
Apr 4th, 2025
Surmodics launches Pounce XL thrombectomy system

Surmodics launches Pounce XL thrombectomy system.

MarketBeat
Jan 5th, 2025
Principal Financial Group Inc. Makes New Investment in Surmodics, Inc. (NASDAQ:SRDX)

Principal Financial Group Inc. makes new investment in Surmodics, Inc. (NASDAQ:SRDX).

MarketBeat
Oct 7th, 2024
Algert Global LLC Makes New $577,000 Investment in Surmodics, Inc. (NASDAQ:SRDX)

Algert Global LLC makes new $577,000 investment in Surmodics, Inc. (NASDAQ:SRDX).

Stock Titan
May 29th, 2024
Surmodics Acquired by GTCR for $627M

Surmodics has agreed to be acquired by GTCR for $43.00 per share in cash, valuing the company at approximately $627 million. This acquisition price represents a 41.1% premium over Surmodics' 30-day average closing price through May 28, 2024. The deal, approved unanimously by Surmodics' Board, is expected to close in the second half of 2024, subject to shareholder and regulatory approval. Post-acquisition, Surmodics will delist from Nasdaq and become privately held.

Business Wire
May 1st, 2024
Surmodics Reports Second Quarter Of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024. Second Quarter Fiscal 2024 Financial SummaryTotal Revenue of $32.0 million, an increase of 18% year-over-yearTotal Revenue excluding SurVeil™ drug-coated balloon (“DCB”) license fee revenue(1) of $30.9 million, an increase of 19% year-over-yearGAAP net income of $0.2 million, compared to a net loss of $(7.7) million in the prior-year periodAdjusted EBITDA(2) of $4.8 million, compared to $(1.5) million in the prior-year periodSecond Quarter and Recent Business HighlightsOn January 22, 2024, Surmodics announced the successful early clinical use and limited market evaluation (LME) of the Pounce LP (Low Profile) Thrombectomy System, which is designed for removal of acute-to-chronic thrombi and emboli in peripheral arteries ranging from 2 mm to 4 mm, such as those found below the knee.Today, Surmodics is announcing the completion of LME and commercial launch of two new mechanical thrombectomy systems for the peripheral venous and arterial vasculatures, the Pounce Venous Thrombectomy System and the Pounce LP Thrombectomy System. The Pounce Venous Thrombectomy System, which transitioned to commercial launch in March, is designed to remove mixed-morphology, wall-adherent peripheral venous clot in a single treatment session while minimizing the need for thrombolytics.The Pounce LP Thrombectomy System, which transitioned to commercial launch in April, addresses an important unmet need for the prompt removal of acute-to-chronic thrombi or emboli in below-the-knee arteries 2 to 4 mm in diameter while minimizing the need for thrombolytics